Unicycive Therapeutics, Inc. (UNCY) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Unicycive Therapeutics, Inc.

UNCY

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

71M

Biotechnology

0.69USD

0.02 ( 3.30%)

Relative Strenght

94

Volume Buzz

22%

Earning Acce

Yes

Dist 52w H.

62%

Quote Panel

Updated January 14, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

Relative Strength

UNCY

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q4.22

N/A

-0.35
vs -0.17

Q1.23

N/A

-0.29
vs -0.24

Q2.23

N/A

-0.29
vs -0.24

Q3.23

N/A

-0.13
vs -0.37

Q4.23

N/A

-0.16
vs -0.35

Q1.24

N/A

-0.27
vs -0.29

Q2.24

N/A

-0.15
vs -0.29

Q3.24

+100%

NA
vs -0.13

Q4.24

N/A

-0.09
vs -0.16

Q1.25

N/A

-0.10
vs -0.27

Sales Growth

YoY

Current

Estimates

Q3.22

NA

951K vs NA

Q4.22

NA

NA vs NA

Q1.23

NA

675K vs NA

Q2.23

NA

NA vs NA

Q3.23

-100%

NA vs 951K

Q4.23

NA

-271000.00 vs NA

Q1.24

-100%

NA vs 675K

Q2.24

NA

NA vs NA

Q3.24

NA

NA vs NA

Q4.24

+3790%

10M vs -271000

Return on Equity

QoQ

Q4.22

+1144%

11.44
vs -1.20

Q1.23

-239%

-2.39
vs 11.44

Q2.23

-56%

-0.56
vs -2.39

Q3.23

-128%

-1.28
vs -0.56

Q4.23

+205%

2.05
vs -1.28

Q1.24

+86%

0.86
vs 2.05

Q2.24

+13%

0.13
vs 0.86

Q3.24

-15%

-0.15
vs 0.13

Institutionnal Ownership

QoQ

Q4.22

9

9
vs 11

-18%

Q1.23

13

13
vs 9

44%

Q2.23

15

15
vs 13

15%

Q3.23

16

16
vs 15

7%

Q4.23

16

16
vs 16

NA

Q1.24

23

23
vs 16

44%

Q2.24

24

24
vs 23

4%

Q3.24

28

28
vs 24

17%

Earnings Growth

Latest News

UNCY

globenewswire.com

7 hours ago

Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science

UNCY

globenewswire.com

7 hours ago

Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference

UNCY

globenewswire.com

7 hours ago

Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update

UNCY

globenewswire.com

7 hours ago

Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

UNCY

globenewswire.com

7 hours ago

Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024

UNCY

globenewswire.com

16 hours ago

Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024

New Feature Coming Soon, Stay Tuned!

Shape

Shape